Merck & Co Inc <a href=" target="_blank">(MRK.N) has agreed to acquire drugmaker OncoImmune in a deal that will give it control of a drug that could help ease symptoms and reduce deaths in patients ...
Following restricted vaccine approvals and changes to CDC immunization schedules, Merck, Pfizer, GSK and Sanofi are all ...
Moderna posted a smaller-than-expected quarterly loss and reduced its annual operating expenses outlook by $700 million on ...
Moderna lowered the top end of its 2025 revenue forecast by $200 million on Thursday, citing weaker-than-expected sales of ...
Analysts are expecting Moderna to report revenue of $880 million in the third quarter, according to FactSet. The consensus ...
Europe's drugs regulator said on Friday it had launched a real-time review of CureVac's (5CV.DE), COVID-19 vaccine to speed ...
When all is done, Vaxart could get more money in this new deal than it was set to get under its Health and Human Services ...
A study published in The Lancet Child & Adolescent Health looks at myocarditis and vascular and inflammatory diseases after COVID-19 infection and vaccination in children. Prof Saidi (Sam) Mohiddin, ...
MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.
Pfizer (PFE) stock is in focus as the company exceeds Street forecasts with its Q3 2025 results thanks mainly to its COVID ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback